PMID- 29579884
OWN - NLM
STAT- MEDLINE
DCOM- 20180821
LR  - 20220321
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 50
IP  - 2
DP  - 2018 Mar
TI  - Prevalence and Survival of Cancer After Pancreas-Kidney Transplantation.
PG  - 669-672
LID - S0041-1345(17)30930-2 [pii]
LID - 10.1016/j.transproceed.2017.09.064 [doi]
AB  - BACKGROUND: Malignancy is an important cause of mortality in solid organ 
      transplantation. There have been few studies of de novo solid organ malignancy 
      (NSOM) after pancreas-kidney transplantation (PKT). The aim of this study was 
      analyze the prevalence of NSOM and transplant outcomes. METHODS: We studied the 
      development of NSOM after PKT in our center from May 1990 to February 2017. We 
      analyzed demographic characteristics, prevalence of cancer, and survival after 
      cancer diagnosis. We excluded nonmelanoma skin cancer and patients with history 
      of malignancy before transplantation. RESULTS: We included 194 patients who 
      received 206 PKTs (184 simultaneous PKTs and 22 pancreas after kidney 
      transplants) with triple immunosuppressive therapy and basiliximab in more than 
      95%. The mean age at transplantation was 39 +/- 7 years and 74% were male patients. 
      Twelve patients developed malignancies (6.1%). Median time from transplant to 
      NSOM was 6.6 (interquartile range [IQR] 0.2-11.7) years. The malignancies were 2 
      cecal appendix tumors, 2 hematologic tumors, 2 breast tumors, 1 melanoma, 1 
      native kidney tumor, 1 brain tumor, 1 bladder tumor, 1 prostate tumor, and 1 
      leiomyosarcoma. Thirty-five of the 194 patients of the whole cohort died 
      throughout the follow-up, 4 of whom died after NSOM diagnosis (11.4%). Patient 
      and grafts survivals were lower in recipients with tumor compared with recipients 
      without tumor, but the difference was not statistically significant: renal graft 
      survival was 80% vs 90% at 10 years (P = .86); and pancreatic graft survival was 
      45% vs 70% at 10 years (P = .15), respectively. The mean patient survival time 
      from the diagnosis of cancer was 36.6 (IQR 18-54) months. Patient survival after 
      NSOM diagnosis was 90% at 1 year and 50% at 5 years. CONCLUSION: The prevalence 
      of NSOM in our PKT recipients is low, despite the scarce series of published data 
      for comparison. Also hematologic tumors rate is very low, possibly influenced by 
      age and type of induction.
CI  - Copyright (c) 2017 Elsevier Inc. All rights reserved.
FAU - Pendon-Ruiz de Mier, M V
AU  - Pendon-Ruiz de Mier MV
AD  - Nephrology, Reina Sofia University Hospital, Cordoba, Spain; Maimonides 
      Biomedical Research Institute of Cordoba, Research Unit, Cordoba, Spain; 
      University of Cordoba, Cordoba, Spain. Electronic address: 
      mvictoriaprm@gmail.com.
FAU - Aguera, M L
AU  - Aguera ML
AD  - Nephrology, Reina Sofia University Hospital, Cordoba, Spain; Maimonides 
      Biomedical Research Institute of Cordoba, Research Unit, Cordoba, Spain; 
      University of Cordoba, Cordoba, Spain.
FAU - Navarro, M D
AU  - Navarro MD
AD  - Nephrology, Reina Sofia University Hospital, Cordoba, Spain; Maimonides 
      Biomedical Research Institute of Cordoba, Research Unit, Cordoba, Spain; 
      University of Cordoba, Cordoba, Spain.
FAU - Rodriguez-Benot, A
AU  - Rodriguez-Benot A
AD  - Nephrology, Reina Sofia University Hospital, Cordoba, Spain; Maimonides 
      Biomedical Research Institute of Cordoba, Research Unit, Cordoba, Spain; 
      University of Cordoba, Cordoba, Spain.
FAU - Aljama, P
AU  - Aljama P
AD  - Nephrology, Reina Sofia University Hospital, Cordoba, Spain; Maimonides 
      Biomedical Research Institute of Cordoba, Research Unit, Cordoba, Spain; 
      University of Cordoba, Cordoba, Spain.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
SB  - IM
MH  - Adult
MH  - Female
MH  - Graft Survival
MH  - Humans
MH  - *Immunocompromised Host
MH  - Kaplan-Meier Estimate
MH  - Kidney Transplantation/*adverse effects/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*epidemiology/*immunology
MH  - Pancreas Transplantation/*adverse effects/mortality
MH  - Prevalence
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2018/03/28 06:00
MHDA- 2018/08/22 06:00
CRDT- 2018/03/28 06:00
PHST- 2017/07/14 00:00 [received]
PHST- 2017/09/21 00:00 [accepted]
PHST- 2018/03/28 06:00 [entrez]
PHST- 2018/03/28 06:00 [pubmed]
PHST- 2018/08/22 06:00 [medline]
AID - S0041-1345(17)30930-2 [pii]
AID - 10.1016/j.transproceed.2017.09.064 [doi]
PST - ppublish
SO  - Transplant Proc. 2018 Mar;50(2):669-672. doi: 10.1016/j.transproceed.2017.09.064.